1057P Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors

Jianming Xu ,Mei Shi ,Yi Huang ,Yaojun Zhang ,Yunong Gao ,Quanli Gao ,Shi Chen ,Haiping Jiang ,J Li,Kun Wang ,Hanguang Hu ,Tianshu Liu ,Ying Yuan ,Dong Wang ,Ye Xu ,Jing Wang ,Lin Shen ,Yanhong Deng ,Jieer Ying ,Aimin Zang

doi:10.1016/j.annonc.2023.09.2196

1057P Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors

Jianming Xu , Mei Shi + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.09.2196

Copy DOI

#Tislelizumab #Mismatch Repair-deficient Tumors + Show 4 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1057P Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors

Full Text